MedTrace Logo

Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.

NCT01425801 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2018-05-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the pharmacodynamics of single doses of inhaled LAS100977 QD in patients with persistent asthma.

Conditions

Interventions

DRUG

LAS100977 0.313 μg

Dry powder inhalation, once-daily, single-dose

DRUG

LAS100977 0.625 μg

Dry powder inhalation, once-daily, single-dose

DRUG

LAS100977 1.25 μg

Dry powder inhalation, once-daily, single-dose

DRUG

LAS100977 2.5 μg

Dry powder inhalation, once-daily, single-dose

DRUG

Salbutamol 400 μg

Pressurized inhalation suspension, once-daily, single-dose

DRUG

Salbutamol placebo

Pressurized inhalation, once-daily

DRUG

LAS100977 placebo

Dry powder inhalation, once-daily

Sponsors & Collaborators

Principal Investigators

  • Carol Astbury, PhD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-01
Primary Completion
2012-02-01
Completion
2012-02-01

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01425801 on ClinicalTrials.gov